Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations

July 25, 2018

IRVINE, CA and AMSTERDAM, NETHERLANDS – 25 July 2018 – Agendia, Inc., a world leader in precision oncology, today announced the completion of $35 million in financing from investment funds managed by Athyrium Capital Management LP, a leading global investor in innovative, high-growth companies across the healthcare sector. Proceeds from the financing will accelerate commercial…

Read more

An Open Letter to Women With Early-Stage Breast Cancer and Their Healthcare Teams:

June 12, 2018

One of the biggest questions that early-stage breast cancer patients face is whether they will benefit from chemotherapy treatment. Two large scale randomized clinical trials that implement genomic testing have positively addressed this question. The recent results from the TAILORx clinical trial evaluating Oncotype DX are important for patients and their oncologists, but they also…

Read more

Key Studies at the American Society of Clinical Oncology (ASCO) Annual Meeting Demonstrate MammaPrint and BluePrint’s Utility in Personalizing Neoadjuvant Treatment Approaches for Early-Stage Breast Cancer Patients

May 29, 2018

New data from the I-SPY 2 trial highlights residual cancer burden as a prognostic indicator for long-term outcomes in patients pre-selected using MammaPrint NBRST trial reports three-year patient outcomes showing that the use of MammaPrint and BluePrint testing in the neoadjuvant setting can help indicate improved outcomes and survival in patients with a specific subtype…

Read more

Agendia and Angsana to Provide Breast Cancer Risk-of-Recurrence Testing with MammaPrint and BluePrint to Patients in Southeast Asia

May 24, 2018

Partnership will enable women in Singapore, Malaysia, Vietnam, Brunei and Myanmar to access the benefits of MammaPrint® and BluePrint® to personalize treatment management decisions for early breast cancer IRVINE, CA AND AMSTERDAM, NETHERLANDS – 24 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, and Angsana Molecular & Diagnostics…

Read more